India Pharma Outlook Team | Wednesday, 12 August 2026
.jpg "Hyderabad Gets a Major Boost as Amgen Plans New R&D Center")
Hyderabad is set for a major boost as Amgen plans a new R&D center in the city. The center will strengthen the company’s research capabilities in India. It will also expand Hyderabad’s role in global drug research and innovation.
The R&D center is expected to become operational in 2027. It will be Amgen’s eighth laboratory in its global research and development network.
The new facility will be called the Amgen Science and Innovation Center. It will focus on experimental science, data, and technology. The center will work alongside Amgen’s existing technology and innovation operations in Hyderabad.
Amgen already has a strong presence in Hyderabad. The company has been expanding its technology and innovation work in the city. The new center will add another layer to these operations. It will bring scientific research and advanced technology closer together.
The facility is expected to support research across areas important to Amgen’s global pipeline. It will also connect teams in India with the company’s wider R&D network. The move highlights the growing importance of India in global pharmaceutical research. Hyderabad has become a major base for pharma companies and research operations.
Amgen’s expansion also reflects the city’s growing pool of scientific and technology talent.
Also Read: How Agentic AI Is Revolutionizing Autonomous DMTA Loops?
Hyderabad has developed into one of India’s key pharmaceutical and biotechnology hubs. The city has a large base of pharmaceutical companies, research institutions, and skilled professionals. Its growing technology ecosystem also supports advanced drug research. Amgen’s new center adds to this momentum. It could help attract more high-value research and innovation activities to the region.
The company’s decision also shows how global pharma firms are using India beyond traditional operations. Research, technology, data science, and innovation are becoming bigger parts of their India strategies. The new center could therefore create opportunities across pharmaceutical research and related technology fields.
The Hyderabad investment comes as pharmaceutical companies increase their focus on innovation and advanced research. Amgen’s new facility will strengthen its scientific presence in India. It will also give its global teams access to Hyderabad’s talent and technology ecosystem.
The company expects the center to support its broader research goals. Its work will connect science with data-driven approaches and technology. For Hyderabad, the project is another sign of its growing importance in global pharma R&D. For India, it adds to the country’s expanding role in pharmaceutical research, technology, and innovation.
